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Hereditary hemolytic anemias are a group of disorders with a vari-ety of causes, including red cell membrane defects, red blood cellenzyme disorders, congenital dyserythropoietic anemias, tha-
lassemia syndromes and hemoglobinopathies. As damaged red blood
cells passing through the red pulp of the spleen are removed by splenic
macrophages, splenectomy is one possible therapeutic approach to the
management of severely affected patients. However, except for heredi-
tary spherocytosis for which the effectiveness of splenectomy has been
well documented, the efficacy of splenectomy in other anemias within
this group has yet to be determined and there are concerns regarding
short- and long-term infectious and thrombotic complications. In light of
the priorities identified by the European Hematology Association
Roadmap we generated specific recommendations for each disorder,
except thalassemia syndromes for which there are other, recent guide-
lines. Our recommendations are intended to enable clinicians to achieve
better informed decisions on disease management by splenectomy, on
the type of splenectomy and the possible consequences. As no random-
ized clinical trials, case control or cohort studies regarding splenectomy in
these disorders were found in the literature, recommendations for each
disease were based on expert opinion and were subsequently critically
revised and modified by the Splenectomy in Rare Anemias Study Group,
which includes hematologists caring for both adults and children. 
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ABSTRACT
Introduction
Hereditary hemolytic anemias are a group of disorders
with a variety of causes, including red cell membrane
defects, enzyme disorders, congenital dyserythropoietic
anemias, and hemoglobinopathies. Given the rarity of
these disorders, their optimal management has yet to be
determined. Splenectomy has been suggested as a possible
therapeutic approach to manage severely affected
patients, based on the evidence that abnormal or damaged
red blood cells passing through the spleen red pulp are
removed by the splenic macrophage system. However,
although splenectomy has been commonly used in recent
decades in the clinical management of patients with
severe hematologic phenotypes, its efficacy in many of
these disorders has yet to be determined. Additionally,
concerns remain regarding short- and long-term infectious
complications, and increased risk of cardiovascular com-
plications in later life, including thrombosis and pul-
monary hypertension.1
We first reviewed the literature in PubMed in order to
generate recommendations regarding splenectomy in
hereditary hemolytic anemias. Since no randomized clini-
cal trials, case-control or cohort studies were identified,
the level of evidence considered was lowered to that from
non-analytic studies and case series. Expert recommenda-
tions were developed, and subsequently critically revised
and modified by the Splenectomy in Rare Anemias Study
Group in order to achieve the greatest possible agreement,
which was classified as "full consensus” (100% agree-
ment) or “consensus” (>80% agreement). None of the core
statements achieved a degree of consensus below 80%.
The Grading of Recommendation Assessment,
Developing and Evaluation (GRADE) system was used to
rate the quality of evidence and strength of recommenda-
tions (see Online Supplementary Information).2
We first present general considerations on the possible
complications of splenectomy, including post-splenecto-
my infections and acute and long-term thromboembolic
complications, and types of splenectomy (laparatomic,
laparoscopic and partial). We then discuss the advantages
and complications of splenectomy for each of the specific
hereditary hemolytic anemia disorders, concluding with
specific recommendations when possible.
Splenectomy complications
Post-splenectomy infections
Given the role of the spleen in immune competence and
blood filtration, there is a risk of overwhelming post-
splenectomy infection (OPSI), which is highest with
encapsulated micro-organisms such as Streptococcus pneu-
moniae, Neisseria meningitidis and Haemophilus influenza.3
Asplenia is also an important risk factor for serious infec-
tions with Plasmodium, Capnocytophaga canimorsus and C.
cynodegmi (after an animal bite), Babesia spp. (after a tick
bite), and Bordetella holmesii.4-6 The risk of post-splenecto-
my sepsis may vary according to the indication for
splenectomy (intermediate risk in spherocytosis and high-
er in other inherited anemias),7 patient’s age at the time of
surgery (highest before the age of 5 years),3 and time since
the splenectomy was performed (risk highest during the
first year after the intervention). However, the risk proba-
bly remains elevated for life.8,9 Given the high risk of OPSI
at a young age, splenectomy should not normally be per-
formed before 5 years of age.
It is difficult to estimate the current risk of OPSI in sub-
jects aged >5 years as most studies are retrospective and
include patients with heterogeneous diseases who were
not fully immunized. It is possible that the widespread use
of conjugated vaccines will significantly reduce the risk of
OPSI. In fact, a recent retrospective study in which 141
consecutive children undergoing splenectomy during
1991-2010 were analyzed indicated that ten of the 11
patients who developed post-splenectomy sepsis had an
additional underlying immune deficiency.10 However, in a
recent prospective, multicenter cohort study of German
patients with severe sepsis or septic shock, S. pneumoniae
sepsis was more frequent among splenectomized patients
than among those with a normal functional spleen (42%
versus 12%, respectively; P<0.001). It is of note that less
than half of the OPSI patients in this study had received
pneumococcal vaccination before splenectomy, despite
national and international guidelines.11
Strategies to reduce the development of OPSI include: (i)
patient’s education, including advice to take urgent action
in response to febrile episodes; (ii) vaccination and (iii)
prophylactic anti-microbial therapy. Detailed guidelines
regarding the prevention and treatment of infections in
splenectomized or asplenic patients are available through
the British Committee for Standards in Haematology12 and
American Academy of Pediatrics (Red Book 30th edition,
2015), to which the reader is referred.
Post-splenectomy thromboembolic complications 
It has been reported that, following splenectomy, there
is an increased risk of early and late venous and arterial
thrombosis1,13 including acute splenic and portal vein
thrombosis (SPVT)14 and delayed severe life-long compli-
cations.15
Acute splenic and portal vein thrombosis 
Acute SPVT after splenectomy is an early and life-
threatening complication, which can lead to bowel
ischemia and/or portal hypertension. This complication
has been related to stasis in the splenic vein remnant.14 The
risk varies depending on the underlying disorder. In 2008,
Krauth et al. reviewed prospective and retrospective stud-
ies and found that 11/89 patients with hemolytic disease
developed SPVT (12.3%) while only 2/118 patients (1.7%)
of those with immune thrombocytopenia had SPVT.
None of 122 patients who underwent splenectomy
because of trauma developed this complication.14,15 Large
spleen size has also been identified as a risk factor for the
development of SPVT. Although there are no well-
designed randomized trials comparing the risk of SPVT
after open splenectomy versus laparoscopic splenectomy,
the surgical approach does not seem to affect the inci-
dence of SPVT.16 Screening for thrombophilia has not been
shown to allow early identification of patients at risk of
SPVT after splenectomy.17
A study in which contrast-enhanced computed tomog-
raphy was used for the diagnosis of SPVT showed that the
median time between splenectomy and the appearance of
asymptomatic SPVT was 6 days (range, 3-11 days).18 A
Canadian study of 40 patients suggested that an appropri-
ate time for Doppler/ultrasound surveillance to diagnose
SPVT is 1 week following splenectomy.19
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Most patients with documented SPVT are treated with
anticoagulant therapy (i.e. intravenous heparin followed by
oral anticoagulants) for a variable period ranging between 3
to 6 months. In one study, the majority of treated patients
had documented complete (57/90, 63.3%) or at least partial
(13.3%) resolution of the thrombus. However, 7.7% of this
latter population showed persistence of thrombus, while
15.5% developed a cavernoma or portal hypertension.14
The role of prophylactic antithrombotic therapy is
unknown as strategies in the various cohorts or case
reports were extremely heterogeneous in terms of dura-
tion of prophylaxis. A randomized study comparing dif-
ferent durations of postoperative antithrombotic prophy-
laxis after laparoscopic abdominal surgery was terminated
early due to the low incidence of thrombosis.16
Late cardiovascular events
Arterial and venous thromboembolism 
An increased risk of vascular complications after
splenectomy was first described in a group of 740 World
War II veterans whose spleen was removed because of
trauma. It was seen that these subjects had a significantly
increased risk of death from ischemic heart disease com-
pared to controls (relative risk, 1.85).15 Data from a Danish
Registry identifying all splenectomized patients from
1996-2005 showed that the long-term (>1 year) risk of
venous thromboembolism remained approximately 3-fold
higher in patients who had undergone splenectomy
because of trauma than in the general population.20 The
contribution of other trauma complications to thrombotic
risk was not, however, evaluated. The long-term risk of
venous thromboembolism was highest in patients
splenectomized for malignant hematologic disorders and
hemolytic anemias.
Pulmonary arterial hypertension 
Splenectomy has been reported to be a risk factor for the
development of pulmonary arterial hypertension,21 partic-
ularly in patients with hemolytic disorders.22-24 Loss of
splenic function is associated with increased numbers of
platelets and also enhances their activation, promoting
pulmonary microthrombosis and adhesion of red cells to
the endothelium.25 The spleen also plays a critical function
in the removal of senescent and damaged erythrocytes. 
Surgical approach
Laparotomic splenectomy 
The traditional approach to splenectomy has been by
laparotomy. This approach allows for a careful search for
an accessory spleen which, if left behind, may cause recur-
rence of anemia.10 The disadvantages of open splenectomy
are mainly surgical morbidity and abdominal wall scar-
ring.26 Laparoscopic splenectomy has become feasible
with progress in minimally invasive techniques.27
Laparoscopic splenectomy
Laparoscopic splenectomy is currently considered the
gold standard technique for removal of a normal sized or
slightly enlarged spleen and is preferred to open splenec-
tomy. Compared to open splenectomy, laparoscopic
splenectomy: (i) is less traumatic; (ii) is associated with
fewer complications; (iii) requires shorter hospital stays;
(iv) has a better cosmetic outcome; and (v) overall, has a
lower cost. However, it should only be performed by
experienced surgeons.28 Nowadays, laparoscopic splenec-
tomy is possible and safe also for massively enlarged
spleens, but in such cases is associated with longer operat-
ing times and longer stays in hospital.29 Perioperative
splenic artery embolization has been found to be useful
and reduces the complications of massive spleen laparo-
scopic splenectomy.30 Moreover, selective splenic artery
embolization, carried out in steps, will reduce spleen size
and alleviate cytopenias.31
A preoperative assessment of splenic size by ultrasound
is recommended. Although three-dimensional computed
tomography is considered to be more accurate, it does not
provide significant advantage in estimating spleen size and
its use should be limited to those cases in which additional
information about the anatomy is required prior to sur-
gery.32
Splenectomy recommendations 
-For prompt diagnosis of SPVT at least one Doppler ultrasound
study should be carried out on day 7 after splenectomy (agreed by
86% of experts) (grade 2 recommendation, grade C evidence).
A. Iolascon et al.
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Table 1. Summary of splenectomy recommendations for hemolytic disorders.
Disease When splenectomy recommended? *
Hereditary spherocytosis Patient is transfusion-dependent or suffers severe anemia.
Patient has moderate disease: decision based on spleen size and quality of life parameters.
No need to perform cholecystectomy.
Pyruvate kinase deficiency Consider if patient is transfusion-dependent or severely anemic.
Cholecystectomy should be performed at time of splenectomy.
Splenectomy in congenital non-spherocytic Consider if patient is transfusion-dependent and/or has massive splenomegaly and/or has
hemolytic anemia due to G6PD deficiency symptomatic splenomegaly.
Hereditary stomatocytosis Contraindicated.
Congenital dyserythropoietic anemia type II Consider if patient is transfusion-dependent and/or has symptomatic splenomegaly.
Sickle cell disease Patient has had two acute splenic sequestration crises and/or has massive splenomegaly
and/or suffers symptomatic hypersplenism.
Unstable hemoglobin Consider only if patient has transfusion-dependent anemia and/or symptomatic splenomegaly.
*For all indications splenectomy should be performed after 6 years of age. G6PD: glucose-6-phosphate dehydrogenase.
Partial splenectomy 
In an attempt to reduce the infectious risk of total
splenectomy, especially for children less than 6 years of
age who suffer severe anemia or are transfusion-depen-
dent, partial splenectomy has been increasingly used in
recent years. In partial splenectomy, usually 80-90% of the
enlarged spleen is removed. Partial splenectomy was ini-
tially performed using an open splenectomy approach but
laparoscopic and robotic approaches have recently been
introduced.33 Nevertheless, partial splenectomy should
always be performed by an experienced surgeon.
Disease-specific recommendations
A detailed discussion of the clinical pictures of and diag-
nostic approaches to hereditary hemolytic disorders is
beyond the scope of this manuscript. Data available on the
advantages and complications of splenectomy in heredi-
tary hemolytic anemias and expert recommendations are
summarized in Table 1. It should be appreciated that data
for some disorders are so sparse that no recommendations
could be generated.
Hereditary spherocytosis
Following thalassemia syndrome and sickle cell disease
(SCD), hereditary spherocytosis (HS) is the most common
form of congenital hemolytic anemia with an incidence of
approximately 1:2000 and a dominant transmission in
about 70-80% of cases. HS is caused by mutations in
genes encoding α- and β-spectrin and other proteins
involved in the attachment of the cytoskeleton to the
overlying lipid bilayer (ankyrin, band 3 and protein 4.2).
Defects in these structural proteins render the red blood
cells spherical, rigid and susceptible to premature destruc-
tion in the spleen.34-37 Clinically, patients with HS are
grouped into three categories according to disease severi-
ty: mild, moderate and severe (Table 2).36
Long-term thrombotic complications of splenectomy
In 1997, Schilling found that the rate of arteriosclerotic
events (stroke, myocardial infarction, coronary or carotid
artery surgery) in patients older than 40 years of age with
HS was 5.6-fold higher in asplenic patients than in HS
patients with an intact spleen, with the first event occur-
ring one or more decades following splenectomy.38 This
was further confirmed in his follow-up study in which the
hazard ratio for arterial events was 7.2 in HS patients who
underwent splenectomy compared to affected patients
who did not undergo splenectomy. In addition, affected
patients who underwent splenectomy had a hazard ratio
of 3 for developing venous events as compared to HS
patients who did not undergo splenectomy.39
However, only a few patients with HS who developed
stroke, pulmonary emboli or pulmonary arterial hyperten-
sion following splenectomy have been reported.24,40-42
Moreover, Buchanan et al. studied 39 adults with HS and
found no evidence of thrombotic manifestations despite a
long follow up (median 25 years).43
Splenectomy
Splenectomy in HS usually results in disappearance of
anemia and a clear decrease of hemolytic markers. In the
large HS series reported by Mariani et al., the median
hemoglobin increase after splenectomy was 3 g/dL (10.8
to 13.9 g/dL), associated with a decrease of reticulocyte
count (from 337 to 51×109/L) and unconjugated bilirubin
(from 32.5 to 12 mmol/L).44
Due to increasing awareness of post-splenectomy com-
plications, the rate of splenectomy has declined in the last
decade. During the period from 1980 to 2005, splenecto-
my was performed in only 20% of HS patients.44 In gener-
al, splenectomy is not indicated in patients with mild HS,
whereas it is usually necessary in severe cases, albeit
delayed if possible until the age of 6 years (Table 2). In the
intermediate categories the indications for splenectomy
are less clear. One indication is symptomatic/painful
splenomegaly with associated thrombocytopenia or
leukopenia that affects the patient’s quality of life. For
young adult patients, unacceptable cutaneous jaundice
(usually in patients with concomitant Gilbert genotype)
may become a social problem that balances a decision
towards splenectomy.
Available guidelines for splenectomy
Guidelines for the diagnosis and management of HS,
including splenectomy were published on behalf of the
General Haematology Task Force of the British
Committee for Standards in Haematology in 2004 and
updated in 2011.45,46 In agreement with previous recom-
mendations, the laparoscopic approach is preferred if
trained surgeons are available; in children undergoing
splenectomy, the gall bladder should be removed con-
comitantly if symptomatic gallstones are present (Table 3).
We referred to previously published guidelines when con-
sidering two particular clinical situations: (i) whether
splenectomy should accompany cholecystectomy when
biliary stones are present; and (ii) the role of partial
splenectomy, particularly in children younger than 6 years
of age with severe HS.
Splenectomy and cholecystectomy
It was previously suggested that there is an increased
risk of intrahepatic choledocholithiasis following splenec-
tomy44 and the 2004 guidelines suggested that for children
with HS who require cholecystectomy the spleen should
Splenectomy in hereditary hemolytic anemias
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Table 2. Indications for splenectomy in hereditary spherocytosis based on severity of disease*.
Disease Hemoglobin Reticulocyte Bilirubin Indication for splenectomy 
severity (g/dL) count (%) (mmol/L)
Severe < 8 > 10 > 51 Indicated, delay until age >6 years
Moderate 8 - 12 > 6 > 34 Individually tailored based on spleen size and quality of life parameters
Mild 11 - 15 3 - 6 17 - 34 Not indicated
*severity of disease based on reference 35.
always be removed.45 This recommendation was based on
expert opinion despite little supportive data in the litera-
ture; the recommendation was changed in subsequent
guidelines to indicate that this issue remains
controversial.46 In a recent study, of 32 pediatric patients
with HS who underwent cholecystectomy, 27 underwent
synchronous splenectomy. However, none of the five
patients who underwent cholecystectomy without
splenectomy experienced signs or symptoms consistent
with gallstones over a median follow-up of 15.6 years.47
Similarly, in a recent study of children aged 4-17 years
studied during 2009-2012, simultaneous cholecystectomy
(for cholelithiasis) and splenectomy was performed in
fewer than half of the patients.48 We recommend that indi-
cations for splenectomy when cholecystectomy is
required should not differ from those for splenectomy
when cholecystectomy is not planned (Tables 1 and 2).
Partial splenectomy
In an attempt to reduce the infectious risk following
total splenectomy, especially for children less than 6 years
of age who suffer severe anemia or are transfusion-depen-
dent, partial splenectomy has been increasingly performed
in recent years. Several studies indicate that partial
splenectomy reduces the rate of hemolysis and increases
red blood cell lifespan while maintaining efficient splenic
phagocytic function.49-50 In a recently published follow-up
study, Pincez et al. reported on 79 HS children who under-
went partial splenectomy using an open splenectomy
approach between 1985 and 2013. In this population, 39
children were less than 5 years of age at the time of
splenectomy (mean age at surgery, 4.3±0.6 years) and
most were transfusion–dependent (31/39). Following par-
tial splenectomy (mean follow up of 12±0.9 years) there
were drastic reductions in transfusion rate and increases in
hemoglobin levels that were compatible with normal
growth while maintaining efficient spleen function in
96% of cases.51 On the other hand, this approach reduced
but did not totally suppress hemolysis and was associated
with later development of gallstones, and splenic remnant
regrowth. Finally, 50% of the 39 severely affected young
HS children required total splenectomy in a median of 5
years following partial splenectomy at an age when total
splenectomy was much safer.51 Falling hemoglobin levels
and discomfort due to spleen remnant regrowth were the
most common indications for this procedure. A recently
published systematic review and meta-analysis comparing
HS patients undergoing total splenectomy (1941 children)
versus partial splenectomy (283 children) confirmed that
although total splenectomy was more effective than par-
tial splenectomy in increasing hemoglobin levels (increas-
es of 3.6 g/dL and 2.2 g/dL, respectively) and in reducing
reticulocyte counts (by 12.5% and 6.5%, respectively), the
outcome following partial splenectomy was stable for at
least 6 years. There were no cases of OPSI.52 In this meta-
analysis, with an overall short follow-up, recurrence of
symptoms following partial splenectomy was uncommon
(5-10%) and secondary splenectomy was indicated in only
5% of children. Thus, partial splenectomy still needs to be
evaluated in larger series with longer term follow-up. In
view of these conflicting data no recommendations
regarding partial splenectomy in HS could be generated by
the group.
Pyruvate kinase deficiency
Pyruvate kinase (PK) deficiency is the most common
glycolytic defect causing congenital non-spherocytic
hemolytic anemia, having an incidence of 1:20,000 in
white individuals.53 PK converts phosphoenolpyruvate to
pyruvate, generating 50% of the total red cell ATP. PK-
deficient red blood cells are damaged due to lack of energy
Splenectomy recommendations 
- Splenectomy is recommended in HS patients who are transfu-
sion-dependent or suffer severe anemia (agreed by 100% of
experts) (Grade 2 recommendation, grade C evidence).
-Indications for splenectomy in the intermediate forms of HS
should be individually tailored based on spleen size and quality of
life parameters (agreed by 95% of experts) (grade 2 recommenda-
tion, grade C evidence).
A. Iolascon et al.
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Table 3. Splenectomy guidelines in hereditary spherocytosis –2011 update45 and the authors’ recommendations.
N. Guidelines 2011 Authors' recommendations
1 The laparoscopic approach to splenectomy is associated with less pain, shorter hospital stay and No change.
better cosmetic appearance; but is dependent on the availability of appropriately trained surgeons, 
and suitable equipment (grade 1 recommendation, grade B evidence).
2 In children undergoing splenectomy, the gall bladder should be removed concomitantly if there are No change.
symptomatic gallstones (grade C evidence, grade 2 recommendation).
3 In children who require cholecystectomy for symptoms of gallstones the use of concurrent splenectomy is In children > 6 years
controversial. It may be associated with a decreased risk of common bile duct stones in the future, but is also of age concomitant 
associated with a risk of post-splenectomy sepsis (grade 2 recommendation, grade C evidence). splenectomy is indicated 
according to severity 
of anemia (Table 1). 
4 When splenectomy is indicated, ideally it should be done after the age of 6 years (grade 2 recommendation, No change.
grade C evidence).
5 Partial splenectomy is theoretically associated with a decreased risk of post-splenectomy sepsis, but it is No consensus 
possible that further surgery may be needed for either recurrence of hematologic problems or symptomatic among our experts.
cholelithiasis (grade 2 recommendation, grade C evidence).
* Reference 45 The Grading of Recommendation Assessment, Developing and Evaluation (GRADE) system was used to rate quality of evidence and strength of recommenda-
tions.
to support membrane ion transport and to maintain mem-
brane structure and are, therefore, cleared by the spleen
and liver. Clinically, PK deficiency has been categorized
into mild, moderate and severe forms (Table 4).54-55
Results of splenectomy
Small retrospective studies suggest that splenectomy may
result in a moderate increase in hemoglobin levels of
approximately 1.8 g/dL (range, 0.4–3.4 g/dL), together with
a conspicuous rise of reticulocytes (up to 50-70%, a typical
feature of PK deficiency) and increased amounts of indirect
bilirubin, even if the anemia becomes less severe.54 Analysis
of the results of a recent international, multicenter registry
study involving 144 patients56 suggested that splenectomy
was performed mainly to reduce transfusion burden and
resulted in improved anemia, and thus enhanced quality of
life. The median pre-splenectomy hemoglobin concentra-
tion was 7 g/dL and, surgery reduced the transfusion bur-
den in 91% of cases. Fifty-three patients (66%) underwent
cholecystectomy at a median age of 14 years (range, 2.6-
60.4 years), of whom 35 (37%) were splenectomized.
Importantly this study showed that transfusion-dependen-
cy and moderate anemia persisted despite splenectomy in
more than half of the patients, suggesting that surgery is
less effective in PK deficiency than in HS.
Indications for splenectomy
Splenectomy may be beneficial in patients with high
transfusion requirements. It may also be considered in
patients with low transfusion requirements who may sub-
sequently become transfusion independent following
splenectomy, although this is difficult to predict. Although
splenectomy does not arrest hemolysis, it reduces and
sometimes eliminates the transfusion requirement in most
transfusion-dependent cases. The response to surgery of
other affected family members may help in predicting the
therapeutic efficacy of splenectomy.54,55 Optimal timing of
surgery is unclear and needs to be considered individually
weighing up the life-long risks (infection, thromboem-
bolism) against the likely benefits.
Cholecystectomy and splenectomy
As for HS, splenectomy should also be considered in
patients requiring cholecystectomy to avoid second surgery.
However, in contrast to HS, in PK deficiency gallstones are
also common in splenectomized patients, and therefore
cholecystectomy should accompany splenectomy. 
Partial splenectomy 
Partial splenectomy was reported to be unsuccessful in
two patients with PK deficiency and effective in one
patient, who achieved an increase in baseline hemoglobin
and reduction in transfusion rate.57
Other therapeutic options for PK deficiency that should
be considered include HLA-matched sibling allogeneic
transplantation,58 and new therapies which are still under
investigation, including the enzyme activator (AG-348)59
and gene therapy.60
Congenital non-spherocytic hemolytic anemia due 
to glucose-6-phosphate dehydrogenase deficiency 
Patients with glucose-6-phosphate dehydrogenase defi-
ciency rarely suffer hemolytic anemia in the steady state and
hemolysis is triggered by an exogenous factor. Some muta-
tions of glucose-6-phosphate dehydrogenase do, however,
result in chronic hemolysis without precipitating causes.
These mutations are more severe than the more commonly
occurring polymorphic forms of the enzyme. The severity of
anemia ranges from borderline to transfusion-dependent. In
2004, Hamilton et al. identified nine transfusion-dependent
patients in the literature: seven responded to splenectomy
and became transfusion-independent.61 Luzzatto and Poggi
suggested that splenectomy should be performed if
splenomegaly becomes a physical encumbrance, or if there
is evidence of hypersplenism and if the anemia is severe.62
Splenectomy recommendations 
-Splenectomy should be considered in patients with PK deficiency
who are transfusion-dependent or do not tolerate the anemia (agreed
by 91% of experts) (grade 2 recommendation, grade C evidence).
-Cholecystectomy should be performed together with splenectomy
(agreed by 86% of experts) (grade 2 recommendation, grade C evi-
dence).
Splenectomy recommendations
-Splenectomy should be considered in patients with congenital
non-spherocytic hemolytic anemia due to glucose-6-phosphate
dehydrogenase deficiency who are transfusion-dependent and/or
have symptomatic splenomegaly. (agreed by 100% of experts)
(grade 2 recommendation, grade C evidence)
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haematologica | 2017; 102(8) 1309
Table 4. Indications for splenectomy in pyruvate kinase deficiency based on severity of disease*.
Disease Age Clinical Median hemoglobin Transfusion Indication 
severity at diagnosis manifestations (g/dL) requirement for splenectomy
Severe Birth/infancy Most patients suffer severe  6.8 Transfusion-dependent Indicated after 
neonatal jaundice requiring age of 6 years
exchange transfusion, 
median age at diagnosis 4, 
almost all transfusion-dependent
Moderate Variable, childhood Moderate anemia 9 Confined to exacerbations Not indicated 
to adult occasional exacerbations
Mild Variable, childhood to adult Lifelong history 11 Rare Not indicated
of mild anemia
Severity of disease based on references 54 and 55.
Pyrimidine-5’-nucleotidase deficiency 
Deficiency of erythrocyte pyrimidine-5’-nucleotidase
is the most common inherited abnormality of nucleotide
metabolism causing hemolytic anemia of moderate
severity.55,63 Transfusions are rarely required.
Splenectomy has been associated with variable increases
in hemoglobin levels.64-67 Portosplenomesentric venous
thrombosis was described in one patient with pyrimi-
dine-5’-nucleotidase following splenectomy due to trau-
ma.68 As there are insufficient data regarding the efficacy
and complications of splenectomy in this disorder no rec-
ommendations could be made. 
Hereditary stomatocytosis 
Hereditary stomatocytosis (HSt), comprising both
dehydrated and overhydrated types, is a dominantly
inherited disorder in which there is altered red blood cell
membrane permeability to monovalent cations (Na+ and
K+), with consequent changes in intracellular cation con-
tent and red cell volume. Dehydrated HSt is the most
common form of HSt, with an incidence of approximate-
ly 1:50,000 births. Overhydrated HSt  is a very rare sub-
type, with only 20 cases having been reported world-
wide. The recent identification of genes mutated in HSt
has improved the diagnosis and understanding of the
pathophysiology of this group of disorders. To date, a
total of five different genes encoding membrane proteins
have been reported to be responsible for red blood cell
volume alterations: three lead to overhydrated HSt [AE1
(also termed SLC4A1), RHAG and GLUT1 (also termed
SCL2A1)69,70 and two to dehydrated HSt (PIEZO1 and
KCNN4, encoding the Gardos channel)]71-75. Reviews on
the clinical picture and molecular pathogenesis have
recently been published.37,76
Splenectomy
A high risk of thromboembolic complications follow-
ing splenectomy in HSt was first described by Stewart
and colleagues (1996) in nine splenectomized adults.77 In
their seven families four had overhydrated HSt and the
remaining dehydrated HSt. Both groups suffered from
serious late thrombotic complications, sometimes recur-
rent over years, including deep vein thrombosis, pul-
monary emboli, superficial thrombophlebitis, portal vein
thrombosis, intracardiac mural thrombosis, arterial
thrombosis, and pulmonary arterial hypertension. Four
of the nine patients died. No such complications were
observed in six affected before splenectomy. Since this
original observation there have been at least four addi-
tional reports of individuals with overhydrated or dehy-
drated HSt who developed severe thrombotic complica-
tions.78-81
Given the retrospective, incomplete, and anecdotal
nature of the description of thromboembolic complica-
tions following splenectomy in HSt, it is impossible to
estimate the precise risk of this procedure, but it is appar-
ent that there is a high risk and that splenectomy, which
is only partially effective in overhydrated HSt and inef-
fective in dehydrated HSt, should be avoided. In patients
with HSt who were mistakenly misdiagnosed as having
HS and underwent splenectomy, life-long anti -
coagulation should be considered.
Congenital dyserythropoietic anemia
Congenital dyserythropoietic anemia (CDA) is a group
of rare red blood cell disorders characterized by ineffective
erythropoiesis, pathognomonic cytopathology of nucleat-
ed red blood cells in bone marrow and increased iron
absorption with secondary hemochromatosis.82 Based on
morphological criteria, subsequently supported by genetic
analysis, three types have been described (I-III). More
recently CDA IV was defined and several additional
unclassified patients have been characterized.83 CDA II is
the most common subtype, with more than 200 patients
described in the literature, followed by CDA I with
approximately 100 patients.82
Splenectomy in congenital dyserythropoietic anemia I
Two case series of 13 severely anemic, mostly transfu-
sion-dependent patients who had undergone splenectomy
were identified.84,85 Six of those patients became transfu-
sion-independent following splenectomy, while seven had
no improvement in hemoglobin levels. Long-term follow-
up of six patients revealed that three had died, one due to
pulmonary arterial hypertension and the other two due to
overwhelming sepsis. Because of inconsistent responses
and possible complications, splenectomy should probably
be reserved for patients manifesting worsening anemia,
and/or significant thrombocytopenia or leukopenia or for
patients with massive, painful splenomegaly. Due to
paucity of data no recommendation regarding splenecto-
my in CDA I could be made.
Splenectomy in congenital dyserythropoietic anemia II
Heimpel et al. reported on 22 patients who underwent
splenectomy at a median age of 19.9 years.86 Hemoglobin
concentration increased in all patients from an average of
9.2 g/dL to 10.3 g/dL. However, in all but one patient,
hemoglobin levels remained below sex-matched reference
values.86 Russo et al. reported that 36% (41/112) of their
patients with CDA II underwent splenectomy and most
(14/17) showed a similar, moderate increase in hemoglo-
bin concentration (9.3±1.2 g/dL to 10.6±1.6 g/dL).87 To
date thrombosis has not been documented in patients
with CDA II following splenectomy. 
Thalassemic syndromes
The authors decided not to discuss thalassemic syn-
dromes since revised guidelines have recently been pre-
sented by the Thalassaemia International Federation
(please visit: www.tif.org).88
Splenectomy recommendations 
- In patients with hereditary stomatocytosis, splenectomy is con-
traindicated (agreed by 100% of experts) (grade 2 recommenda-
tion, grade C evidence).
Splenectomy recommendations 
-In patients with CDA II splenectomy should be considered in
severely anemic patients and/or in those with symptomatic
splenomegaly (agreed by 95% of experts) (grade 2 recommenda-
tion, grade C evidence).
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Sickle cell disease
SCD is a hereditary hemoglobinopathy with a world-
wide distribution: projected numbers of births in 2010
were 237,381 in Africa, 11,143 in the USA and 1,939 in
Europe.89 SCD is caused by a point mutation in the β-glo-
bin gene resulting in the synthesis of a pathological hemo-
globin, HbS.90 Cyclic polymerization/depolymerization of
deoxy-HbS generates dense, dehydrated red cells that play
a central role in the acute and chronic clinical manifesta-
tions of SCD, in which intravascular sickling leads to vaso-
occlusion and impaired blood flow with ischemic/reperfu-
sion injury.90 Some organs, such as the spleen, have been
shown to be more vulnerable to damage from HbS poly-
merization than others organs, due to their peculiar
anatomic organization mainly characterized by sluggish
circulation, low pH and local high pro-oxidant environ-
ment.90,91
Splenectomy
An acute splenic sequestration crisis is defined as acute
abdominal pain and distension associated with spleen
enlargement, a decrease in hemoglobin levels of at least 2
g/dL and stable or high reticulocyte count compared to
that of the patient in steady state.92 Even though the mor-
tality rate of patients with SCD has declined since the
introduction of neonatal screening for the disease, vaccina-
tion programs and parental education, acute splenic
sequestration crisis is still a life-threatening complication.93
The clinical management of such crises, with acute splenic
sickling and spleen blood entrapment, is based on rapid
correction of hypovolemic shock by infusion of crystal-
loids and packed red cells. Although international guide-
lines and consensus statements on the management of
acute splenic sequestration crisis are not available,
splenectomy is usually recommended after two such
crises requiring urgent transfusion.92-95
Hypersplenism, defined as chronic splenic enlargement
with lowered hemoglobin concentration and decreased
platelet and leukocyte counts, is the second major indica-
tion for splenectomy in SCD patients.92-95 Splenectomy is
usually indicated if there is hypersplenism, pressure
effects of the spleen or failure to thrive. Transfusion is
often ineffective in such children because of red blood cell
sequestration in the enlarged spleen.
Although splenectomy is the treatment for recurrent
acute splenic sequestration crises and hypersplenism in
SCD, there is no evidence that it increases hemoglobin
level, decreases hemolysis or improves patients’ survival.96
Splenectomy may, however, increase thromboembolism.
Limited evidence is available about any possible increased
incidence of pulmonary arterial hypertension or pain fre-
quency in SCD patients.97
Laparoscopic splenectomy is generally used in children
with SCD. It is performed after preoperative transfusion
or exchange transfusion to decrease the percentage of
HbS. The major limitations to using a laparoscopic
approach in SCD children are the size of the spleen, with
its local adhesions, and the longer duration of the opera-
tion. Although laparoscopic splenectomy has some posi-
tive aspects, such as the shorter duration of hospitaliza-
tion, its impact on the incidence of post-operative severe,
acute, SCD-related complications, including acute chest
syndrome, is still unclear.98,99 To date there are no real
advantages, in terms of hematologic phenotype and infec-
tive risk, from partial splenectomy rather than total
splenectomy in children with SCD.100
Thus, guidelines on the clinical management of acute
splenic sequestration crisis in SCD are needed. The guide-
lines should present parameters for and timing of splenec-
tomy, with accompanying surgical approaches.
Indications are likely to vary depending on environmental
factors, including the availability of safe blood transfu-
sions and the spectrum of infections. Future multicenter
studies should be designed to address these issues.
Unstable hemoglobin
Globin mutations that destabilize hemoglobin tetramers
constitute a very rare cause of hemolytic anemia. The clin-
ical pattern of hemolytic anemia related to unstable hemo-
globin is extremely variable. Severely affected patients,
particularly those with hyperunstable hemoglobin, pres-
ent early in childhood and may require chronic transfusion
therapy. Thrombotic complications following splenecto-
my have been described in nine patients (with Hb
Bridlington/HbTaybe, Hb Taybe, Hb Mainz, Hb Olmsted,
Hb Madrid and Hb Perth).101-106 The thrombotic events,
including pulmonary emboli, pulmonary arterial hyper-
tension, arterial stroke and priapism, occurred even 4-32
years after splenectomy. The majority of patients (7/9) had
no or only partial improvement in hemoglobin levels.
Given the anecdotal data, splenectomy should be consid-
ered only when there is severe anemia and/or massive or
symptomatic splenomegaly. 
Splenectomy recommendations 
-In SCD children, splenectomy is recommended after two acute
splenic sequestration crises (agreed by 100% of experts) (grade 2
recommendation, grade C evidence).
-In SCD children, splenectomy is also recommended in patients
with massive splenomegaly and/or hypersplenism (agreed by 90%
of experts) (grade 2 recommendation, grade C evidence).
Splenectomy recommendations 
-In patients with unstable hemoglobin splenectomy should be
considered when the spleen is very large and/or there is evidence of
hypersplenism (agreed by 95% of experts) (grade 2 recommenda-
tion, grade C evidence).
Splenectomy in hereditary hemolytic anemias
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